The US Food and Drug Administration (FDA) has granted Fast Track designation for Agenus’ combination therapy for the treatment of colorectal cancer.
The FDA awarded the Fast Track status for the investigation of a botensilimab (AGEN1181) and balstilimab (AGEN2034) combination.
The combination therapy has been approved to treat non-microsatellite instability-high (non-MSI-H)/deficient mismatch repair metastatic colorectal cancer patients, with no signs of active liver involvement.